Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904230285> ?p ?o ?g. }
- W2904230285 endingPage "929" @default.
- W2904230285 startingPage "921" @default.
- W2904230285 abstract "Abstract Background Increasing antimicrobial resistance among pathogens that cause complicated intraabdominal infections (cIAIs) supports the development of new antimicrobials. Eravacycline, a novel member of the fluorocycline family, is active against multidrug-resistant bacteria including extended-spectrum β-lactamase (ESBL) and carbapenem-resistant Enterobacteriaceae. Methods IGNITE4 was a prospective, randomized, double-blind trial. Hospitalized patients with cIAI received either eravacycline 1 mg/kg every 12 hours or meropenem 1 g every 8 hours intravenously for 4–14 days. The primary objective was to demonstrate statistical noninferiority (NI) in clinical cure rates at the test-of-cure visit (25–31 days from start of therapy) in the microbiological intent-to-treat population using a NI margin of 12.5%. Microbiological outcomes and safety were also evaluated. Results Eravacycline was noninferior to meropenem in the primary endpoint (177/195 [90.8%] vs 187/205 [91.2%]; difference, –0.5%; 95% confidence interval [CI], –6.3 to 5.3), exceeding the prespecified margin. Secondary endpoints included clinical cure rates in the modified ITT population (231/250 [92.4%] vs 228/249 [91.6%]; difference, 0.8; 95% CI, –4.1, 5.8) and the clinically evaluable population (218/225 [96.9%] vs 222/231 [96.1%]; (difference, 0.8; 95% CI –2.9, 4.5). In patients with ESBL-producing Enterobacteriaceae, clinical cure rates were 87.5% (14/16) and 84.6% (11/13) in the eravacycline and meropenem groups, respectively. Eravacycline had relatively low rates of adverse events for a drug of this class, with less than 5%, 4%, and 3% of patients experiencing nausea, vomiting, and diarrhea, respectively. Conclusions Treatment with eravacycline was noninferior to meropenem in adult patients with cIAI, including infections caused by resistant pathogens. Clinical Trials Registration NCT01844856." @default.
- W2904230285 created "2018-12-22" @default.
- W2904230285 creator A5003906647 @default.
- W2904230285 creator A5015448893 @default.
- W2904230285 creator A5063713898 @default.
- W2904230285 creator A5065319132 @default.
- W2904230285 creator A5068059585 @default.
- W2904230285 creator A5077152126 @default.
- W2904230285 creator A5088076252 @default.
- W2904230285 date "2018-12-18" @default.
- W2904230285 modified "2023-10-05" @default.
- W2904230285 title "IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections" @default.
- W2904230285 cites W1618166169 @default.
- W2904230285 cites W1969500929 @default.
- W2904230285 cites W1969648832 @default.
- W2904230285 cites W2041797411 @default.
- W2904230285 cites W2061669270 @default.
- W2904230285 cites W2078250306 @default.
- W2904230285 cites W2086460365 @default.
- W2904230285 cites W2087242016 @default.
- W2904230285 cites W2088452703 @default.
- W2904230285 cites W2115744065 @default.
- W2904230285 cites W2125808637 @default.
- W2904230285 cites W2135543196 @default.
- W2904230285 cites W2137408524 @default.
- W2904230285 cites W2149186506 @default.
- W2904230285 cites W2149315953 @default.
- W2904230285 cites W2150478590 @default.
- W2904230285 cites W2154007902 @default.
- W2904230285 cites W2156918227 @default.
- W2904230285 cites W2163177484 @default.
- W2904230285 cites W2290753892 @default.
- W2904230285 cites W2294833633 @default.
- W2904230285 cites W2419535666 @default.
- W2904230285 cites W2474294795 @default.
- W2904230285 cites W2513238037 @default.
- W2904230285 cites W2527930446 @default.
- W2904230285 cites W2550643720 @default.
- W2904230285 cites W2583549666 @default.
- W2904230285 cites W2588446477 @default.
- W2904230285 cites W2603039590 @default.
- W2904230285 cites W2735724836 @default.
- W2904230285 cites W2750718612 @default.
- W2904230285 cites W2777879918 @default.
- W2904230285 cites W2786886659 @default.
- W2904230285 cites W2790850087 @default.
- W2904230285 cites W2795817444 @default.
- W2904230285 cites W2888520542 @default.
- W2904230285 cites W2892368225 @default.
- W2904230285 cites W9661049 @default.
- W2904230285 doi "https://doi.org/10.1093/cid/ciy1029" @default.
- W2904230285 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6735687" @default.
- W2904230285 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30561562" @default.
- W2904230285 hasPublicationYear "2018" @default.
- W2904230285 type Work @default.
- W2904230285 sameAs 2904230285 @default.
- W2904230285 citedByCount "112" @default.
- W2904230285 countsByYear W29042302852018 @default.
- W2904230285 countsByYear W29042302852019 @default.
- W2904230285 countsByYear W29042302852020 @default.
- W2904230285 countsByYear W29042302852021 @default.
- W2904230285 countsByYear W29042302852022 @default.
- W2904230285 countsByYear W29042302852023 @default.
- W2904230285 crossrefType "journal-article" @default.
- W2904230285 hasAuthorship W2904230285A5003906647 @default.
- W2904230285 hasAuthorship W2904230285A5015448893 @default.
- W2904230285 hasAuthorship W2904230285A5063713898 @default.
- W2904230285 hasAuthorship W2904230285A5065319132 @default.
- W2904230285 hasAuthorship W2904230285A5068059585 @default.
- W2904230285 hasAuthorship W2904230285A5077152126 @default.
- W2904230285 hasAuthorship W2904230285A5088076252 @default.
- W2904230285 hasBestOaLocation W29042302851 @default.
- W2904230285 hasConcept C126322002 @default.
- W2904230285 hasConcept C141071460 @default.
- W2904230285 hasConcept C168563851 @default.
- W2904230285 hasConcept C197934379 @default.
- W2904230285 hasConcept C203092338 @default.
- W2904230285 hasConcept C2776685102 @default.
- W2904230285 hasConcept C2779375183 @default.
- W2904230285 hasConcept C2908647359 @default.
- W2904230285 hasConcept C44249647 @default.
- W2904230285 hasConcept C501593827 @default.
- W2904230285 hasConcept C535046627 @default.
- W2904230285 hasConcept C71924100 @default.
- W2904230285 hasConcept C86803240 @default.
- W2904230285 hasConcept C89423630 @default.
- W2904230285 hasConcept C94665300 @default.
- W2904230285 hasConcept C99454951 @default.
- W2904230285 hasConceptScore W2904230285C126322002 @default.
- W2904230285 hasConceptScore W2904230285C141071460 @default.
- W2904230285 hasConceptScore W2904230285C168563851 @default.
- W2904230285 hasConceptScore W2904230285C197934379 @default.
- W2904230285 hasConceptScore W2904230285C203092338 @default.
- W2904230285 hasConceptScore W2904230285C2776685102 @default.
- W2904230285 hasConceptScore W2904230285C2779375183 @default.
- W2904230285 hasConceptScore W2904230285C2908647359 @default.
- W2904230285 hasConceptScore W2904230285C44249647 @default.
- W2904230285 hasConceptScore W2904230285C501593827 @default.